AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 342557 — intervention group
Group type: COMPARATOR
Intervention: Control group (similar training without specific treatment)
Number of subjects: 20
Study 30711698 — intervention group
Group type: EXPERIMENTAL
Intervention: 2-dose HPV vaccine
Number of subjects: 1515
Study 30711698 — intervention group
Group type: COMPARATOR
Intervention: 3-dose HPV vaccine
Number of subjects: 1515
Study 30711698 — intervention group
Group type: COMPARATOR
Intervention: Unvaccinated women
Number of subjects: 1515
Study 28290191 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive resistance exercise (PRE)
Number of subjects: 28
Study 28290191 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG)
Number of subjects: 28
Study 26121076 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin-wall introducer needle technique
Number of subjects: 266
Study 26121076 — intervention group
Group type: COMPARATOR
Intervention: Cannula-over-needle technique
Number of subjects: 266
Study 26121076 — intervention group
Group type: EXPERIMENTAL
Intervention: Both techniques
Number of subjects: 266
Study 23899172 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein (54 mg/day) for 6 months
Number of subjects: 20
Study 23899172 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 21742102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed-dose combination of isosorbide dinitrate/hydralazine (FDC I/H)
Number of subjects: 1050
Study 21742102 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1050
Study 19958521 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatibant (low, medium, or high dose)
Number of subjects: 228
Study 19958521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 228
Study 19958521 — intervention group
Group type: EXPERIMENTAL
Intervention: Anatibant (any dose)
Number of subjects: 228
Study 16430668 — intervention group
Group type: EXPERIMENTAL
Intervention: Restrictive transfusion strategy (trigger at 8 g/dl)
Number of subjects: 260
Study 16430668 — intervention group
Group type: COMPARATOR
Intervention: Liberal transfusion strategy (trigger at 10 g/dl)
Number of subjects: 260
Study 15582838 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine (OXC) - 1200 mg
Number of subjects: 32
Study 15582838 — intervention group
Group type: COMPARATOR
Intervention: Phenytoin (PHT) - 360 mg
Number of subjects: 32
Study 10651210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline 25 mg/day
Number of subjects: 8
Study 10651210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline 50 mg/day
Number of subjects: 8
Study 10651210 — intervention group
Group type: EXPERIMENTAL
Intervention: Cibenzoline (25 and 50 mg/day)
Number of subjects: 8
Study 9078539 — intervention group
Group type: EXPERIMENTAL
Intervention: PTHrP139, PTHrP173, PTHrP141 variants
Number of subjects: 0
Study 8450580 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroxyacetone (DHAP)
Number of subjects: 18
Study 8450580 — intervention group
Group type: COMPARATOR
Intervention: Placebo (100 g polyglucose, Polycose)
Number of subjects: 18
Study 2945499 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg loratadine
Number of subjects: 60
Study 2945499 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg loratadine
Number of subjects: 60
Study 2945499 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg loratadine
Number of subjects: 60
Study 2945499 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorpheniramine maleate (CTM) 12 mg
Number of subjects: 60
Study 2945499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2945499 — intervention group
Group type: EXPERIMENTAL
Intervention: All doses of loratadine
Number of subjects: 60
Study 3041936 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol (2.5 to 5.0 mg/d for an average of 328 days)
Number of subjects: 34
Study 3041936 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 3041936 — intervention group
Group type: EXPERIMENTAL
Intervention: Carteolol
Number of subjects: 34
Study 3041936 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 34
Study 30741439 — intervention group
Group type: EXPERIMENTAL
Intervention: PEP uP
Number of subjects: 36
Study 30741439 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 36
Study 30760406 — intervention group
Group type: EXPERIMENTAL
Intervention: TKIs treatment (first-line)
Number of subjects: 61
Study 30760406 — intervention group
Group type: EXPERIMENTAL
Intervention: Detection of T790M mutations using ddPCR
Number of subjects: 61
Study 30760406 — intervention group
Group type: EXPERIMENTAL
Intervention: De novo T790M mutation presence
Number of subjects: 61
Study 28697773 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture treatment for 5 days
Number of subjects: 44
Study 28697773 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture
Number of subjects: 44
Study 28697773 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture
Number of subjects: 44
Study 25040321 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol injected intravenously in 30 to 40 mg boluses, followed by 10 to 20 mg intermittent bolus doses to sedate the patients to Ramsey score of 3 to 4.
Number of subjects: 90
Study 25040321 — intervention group
Group type: COMPARATOR
Intervention: 6 mg of sumatriptan subcutaneously
Number of subjects: 90
Study 23826887 — intervention group
Group type: EXPERIMENTAL
Intervention: Tailored interventions (peer group supervision and individualised telephone consultations)
Number of subjects: 14
Study 23826887 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-rating scale for measuring depressive and anxiety symptoms
Number of subjects: 14
Study 23826887 — intervention group
Group type: EXPERIMENTAL
Intervention: Better patient care
Number of subjects: 14
Study 22186117 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stent (PES)
Number of subjects: 103
Study 22186117 — intervention group
Group type: COMPARATOR
Intervention: Bare metal stent (BMS)
Number of subjects: 103
Study 19097665 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin 100mg once daily
Number of subjects: 530
Study 19097665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 530
Study 19097665 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 530
Study 16817738 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg of rhTSH, IM or IV
Number of subjects: 38
Study 16817738 — intervention group
Group type: COMPARATOR
Intervention: 1 unit of bTSH, IM
Number of subjects: 38
Study 16817738 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 microg of rhTSH, IV
Number of subjects: 38
Study 12766621 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.32 ml of 95% alcohol per kilogram of body weight, mixed with orange juice
Number of subjects: 41
Study 12766621 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 10860330 — intervention group
Group type: EXPERIMENTAL
Intervention: Er,Cr:YSGG laser system
Number of subjects: 67
Study 10860330 — intervention group
Group type: COMPARATOR
Intervention: Conventional air turbine/bur dental surgery
Number of subjects: 67
Study 9356283 — intervention group
Group type: EXPERIMENTAL
Intervention: Olean potato chips (2 oz)
Number of subjects: 57
Study 9356283 — intervention group
Group type: COMPARATOR
Intervention: Triglyceride potato chips (2 oz)
Number of subjects: 57
Study 8482086 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange with albumin as replacement fluid
Number of subjects: 220
Study 8482086 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange with fresh frozen plasma as replacement fluid
Number of subjects: 220
Study 8482086 — intervention group
Group type: COMPARATOR
Intervention: Plasma exchange (both albumin and fresh frozen plasma)
Number of subjects: 220
Study 8482086 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange
Number of subjects: 220
Study 8482086 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-plasma exchange hemoglobin level
Number of subjects: 220
Study 3514368 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg of PGE2 in 2.5 ml of Triacetin gel
Number of subjects: 80
Study 3514368 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of PGE2 gel with conventional oxytocin induction
Number of subjects: 80
Study 3514368 — intervention group
Group type: COMPARATOR
Intervention: Control group (conventional induction)
Number of subjects: 80
Study 29490986 — intervention group
Group type: EXPERIMENTAL
Intervention: Buparlisib plus paclitaxel
Number of subjects: 158
Study 29490986 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus paclitaxel
Number of subjects: 158
Study 27645244 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir (NVR) 200 mg
Number of subjects: 32
Study 27645244 — intervention group
Group type: EXPERIMENTAL
Intervention: Narlaprevir (NVR) 100 mg with Ritonavir (RTV) 100 mg
Number of subjects: 32
Study 25170231 — intervention group
Group type: EXPERIMENTAL
Intervention: Tandospirone (10 mg thrice daily) and pinaverium (50 mg thrice daily)
Number of subjects: 200
Study 25170231 — intervention group
Group type: COMPARATOR
Intervention: Pinaverium (50 mg thrice daily) and placebo
Number of subjects: 200
Study 23697514 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT
Number of subjects: 53439
Study 23697514 — intervention group
Group type: COMPARATOR
Intervention: Chest radiography
Number of subjects: 53439
Study 19778341 — intervention group
Group type: EXPERIMENTAL
Intervention: Study brochure addressing common donor concerns and suggesting specific coping strategies
Number of subjects: 0
Study 19778341 — intervention group
Group type: COMPARATOR
Intervention: Blood center brochure
Number of subjects: 0
Study 19778341 — intervention group
Group type: COMPARATOR
Intervention: Control brochure on healthy eating and exercise
Number of subjects: 0
Study 18096834 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive stroke unit
Number of subjects: 489
Study 18096834 — intervention group
Group type: EXPERIMENTAL
Intervention: Early supported discharge service
Number of subjects: 489
Study 16632762 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary counseling sessions (2 sessions)
Number of subjects: 58
Study 16632762 — intervention group
Group type: COMPARATOR
Intervention: Current standard care
Number of subjects: 58
Study 12357161 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg rofecoxib
Number of subjects: 143
Study 12357161 — intervention group
Group type: COMPARATOR
Intervention: 2 g acetaminophen
Number of subjects: 143
Study 12357161 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 g acetaminophen and 50 mg rofecoxib
Number of subjects: 143
Study 12357161 — intervention group
Group type: COMPARATOR
Intervention: 500 mg vitamin C (placebo)
Number of subjects: 143
Study 10204818 — intervention group
Group type: EXPERIMENTAL
Intervention: Coenzyme Q10 (60 mg twice daily) for 8 weeks
Number of subjects: 59
Study 10204818 — intervention group
Group type: COMPARATOR
Intervention: B vitamin complex (control group)
Number of subjects: 59
Study 7481551 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant interferon-alpha
Number of subjects: 37
Study 2182300 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebulized ketanserin
Number of subjects: 8
Study 2182300 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous ketanserin
Number of subjects: 8
Study 2182300 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 6446424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-amniotic injection of dehydroepiandrosterone sulphate (DHEA-S) (100-200 mg)
Number of subjects: 26
Study 6446424 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous injection of dehydroepiandrosterone sulphate (DHEA-S) (100 mg)
Number of subjects: 26
Study 31897841 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 113
Study 31897841 — intervention group
Group type: EXPERIMENTAL
Intervention: Appendicectomy
Number of subjects: 113
Study 31897841 — intervention group
Group type: EXPERIMENTAL
Intervention: No preference
Number of subjects: 113
Study 31897841 — intervention group
Group type: COMPARATOR
Intervention: Randomisation
Number of subjects: 113
Study 31897841 — intervention group
Group type: COMPARATOR
Intervention: Blinding
Number of subjects: 113
Study 31897841 — intervention group
Group type: COMPARATOR
Intervention: Research participation
Number of subjects: 113
Study 31897841 — intervention group
Group type: COMPARATOR
Intervention: Perception of research risk
Number of subjects: 113
Study 31897841 — intervention group
Group type: COMPARATOR
Intervention: Education level
Number of subjects: 113
Study 29091327 — intervention group
Group type: EXPERIMENTAL
Intervention: Peg‐IFN‐α‐2a add‐on therapy
Number of subjects: 30
Study 29091327 — intervention group
Group type: COMPARATOR
Intervention: TDF alone (NA group)
Number of subjects: 30
Study 26760456 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 135
Study 26760456 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 135
Study 26760456 — intervention group
Group type: EXPERIMENTAL
Intervention: SAD
Number of subjects: 135
Study 26760456 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (HCs)
Number of subjects: 135
Study 24699298 — intervention group
Group type: EXPERIMENTAL
Intervention: Amikacin
Number of subjects: 187
Study 24699298 — intervention group
Group type: COMPARATOR
Intervention: Piperacillin-tazobactam
Number of subjects: 187
Study 22145572 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracorporeal knotting
Number of subjects: 107
Study 22145572 — intervention group
Group type: COMPARATOR
Intervention: Metal endoclip application
Number of subjects: 107
Study 20390813 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 579
Study 20390813 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment
Number of subjects: 579
Study 20390813 — intervention group
Group type: COMPARATOR
Intervention: Routine community care
Number of subjects: 579
Study 17389535 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostate-specific antigen testing (PSA)
Number of subjects: 432
Study 17389535 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision-making control by physicians
Number of subjects: 432
Study 16135583 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrauterine 5‐mL 2% lidocaine
Number of subjects: 66
Study 16135583 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 66
Study 12042267 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 microg desogestrel p.o. daily for 24 weeks with 400 mg testosterone pellets s.c. on day 1 and at 12 weeks
Number of subjects: 66
Study 12042267 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 microg desogestrel p.o. daily for 24 weeks with 400 mg testosterone pellets s.c. on day 1 and at 12 weeks
Number of subjects: 66
Study 12042267 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of oral desogestrel with depot testosterone
Number of subjects: 66
Study 9543120 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment (0.3 mg/kg x week, mean duration = 41 months)
Number of subjects: 94
Study 9543120 — intervention group
Group type: COMPARATOR
Intervention: Untreated group
Number of subjects: 94
Study 9543120 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth Hormone (GH) treatment
Number of subjects: 94
Study 8304654 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose oral acyclovir (800 mg four times daily)
Number of subjects: 47
Study 8304654 — intervention group
Group type: COMPARATOR
Intervention: Preemptive, short-course ganciclovir therapy (5 mg/kg intravenously twice daily for 7 days if CMV shedding occurred)
Number of subjects: 47
Study 2729815 — intervention group
Group type: EXPERIMENTAL
Intervention: lyophilized collagen pads as adjunctive treatment
Number of subjects: 20
Study 2729815 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 20
Study 29247643 — intervention group
Group type: EXPERIMENTAL
Intervention: LFS‐01 (sulforaphene) treatment
Number of subjects: 0
Study 29267760 — intervention group
Group type: EXPERIMENTAL
Intervention: Payment scheme by performance (budget support agreement)
Number of subjects: 0
Study 29267760 — intervention group
Group type: COMPARATOR
Intervention: Control sample (areas without budget support agreements)
Number of subjects: 0
Study 25736524 — intervention group
Group type: EXPERIMENTAL
Intervention: Pagibaximab
Number of subjects: 0
Study 25736524 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 23073723 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 100
Study 23073723 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone 10 mg/day
Number of subjects: 100
Study 21282192 — intervention group
Group type: EXPERIMENTAL
Intervention: DDMM (2 doses of DNA followed by 2 doses of rMVA)
Number of subjects: 0
Study 21282192 — intervention group
Group type: EXPERIMENTAL
Intervention: DMM (1 dose of DNA followed by 2 doses of rMVA)
Number of subjects: 0
Study 21282192 — intervention group
Group type: EXPERIMENTAL
Intervention: MMM (3 doses of rMVA)
Number of subjects: 0
Study 21282192 — intervention group
Group type: EXPERIMENTAL
Intervention: 1/10th-dose DDMM regimen
Number of subjects: 0
Study 19672930 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy (operation within 72 h of admission)
Number of subjects: 72
Study 19672930 — intervention group
Group type: COMPARATOR
Intervention: Conventional management (elective cholecystectomy 3 months later)
Number of subjects: 72
Study 19672930 — intervention group
Group type: EXPERIMENTAL
Intervention: Early laparoscopic cholecystectomy
Number of subjects: 72
Study 19672930 — intervention group
Group type: COMPARATOR
Intervention: Conventional management
Number of subjects: 72
Study 17109579 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingually delivered vitamin B complex
Number of subjects: 41
Study 17109579 — intervention group
Group type: COMPARATOR
Intervention: Orally delivered vitamin B complex
Number of subjects: 41
Study 15080848 — intervention group
Group type: EXPERIMENTAL
Intervention: Tinzaparin 175 anti‐Xa IU/kg/day for 14 days followed by 4500 anti‐Xa IU/day for 28 days
Number of subjects: 100
Study 15080848 — intervention group
Group type: COMPARATOR
Intervention: Placebo administered subcutaneously once daily for up to 42 days
Number of subjects: 100
Study 10649262 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 59994
Study 10649262 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 59994
Study 9312206 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrapulmonary SCT (delivered via dry powder inhaler)
Number of subjects: 0
Study 9312206 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular SCT (IM)
Number of subjects: 0
Study 7865076 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF dentifrices (1000 or 1500 micrograms F/g)
Number of subjects: 474
Study 7865076 — intervention group
Group type: COMPARATOR
Intervention: Na2FPO3 dentifrices (1000 or 1500 micrograms F/g)
Number of subjects: 474
Study 7865076 — intervention group
Group type: EXPERIMENTAL
Intervention: NaF dentifrices
Number of subjects: 474
Study 7865076 — intervention group
Group type: COMPARATOR
Intervention: Na2FPO3 dentifrices
Number of subjects: 474
Study 2511277 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 micrograms of recombinant IFN-gamma given once weekly
Number of subjects: 22
Study 2511277 — intervention group
Group type: COMPARATOR
Intervention: Patients with refractory disease
Number of subjects: 22
Study 240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Prazosin
Number of subjects: 591
Study 240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta adrenergic blocking agents
Number of subjects: 591
Study 240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of beta adrenergic blocking agents with peripheral vasodilators (e.g., hydrallazine, prazosin)
Number of subjects: 591
Study 240112 — intervention group
Group type: COMPARATOR
Intervention: Hydrallazine
Number of subjects: 591
Study 240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics
Number of subjects: 591
Study 240112 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 591
Study 31601424 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline
Number of subjects: 124
Study 31601424 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine
Number of subjects: 124
Study 31601424 — intervention group
Group type: COMPARATOR
Intervention: Escitalopram
Number of subjects: 124
Study 31513552 — intervention group
Group type: EXPERIMENTAL
Intervention: Community empowerment model of combination HIV prevention (Project Shikamana)
Number of subjects: 496
Study 31513552 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 496
Study 28025462 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg
Number of subjects: 1517
Study 28025462 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin 25 mg
Number of subjects: 1517
Study 28025462 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1517
Study 28025462 — intervention group
Group type: EXPERIMENTAL
Intervention: Empagliflozin
Number of subjects: 1517
Study 23153843 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG
Number of subjects: 7812
Study 23153843 — intervention group
Group type: COMPARATOR
Intervention: PCI
Number of subjects: 7812
Study 23153843 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG and PCI
Number of subjects: 7812
Study 20079922 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.59-mg FA intravitreal implant
Number of subjects: 140
Study 20079922 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC) with systemic prednisolone or equivalent corticosteroid
Number of subjects: 140
Study 18956517 — intervention group
Group type: EXPERIMENTAL
Intervention: Involved-node (IN) radiotherapy
Number of subjects: 0
Study 18956517 — intervention group
Group type: COMPARATOR
Intervention: Standard involved-field (IF) radiotherapy
Number of subjects: 0
Study 15983798 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg
Number of subjects: 16
Study 15983798 — intervention group
Group type: COMPARATOR
Intervention: Clonidine 0.2 mg
Number of subjects: 16
Study 15983798 — intervention group
Group type: EXPERIMENTAL
Intervention: Modafinil 200 mg + Clonidine 0.2 mg
Number of subjects: 16